<DOC>
	<DOCNO>NCT01980654</DOCNO>
	<brief_summary>This open-label , Phase 2 study design ass efficacy safety ibrutinib combine rituximab previously untreated subject FL .</brief_summary>
	<brief_title>Study Bruton 's Tyrosine Kinase Inhibitor Combination With Rituximab Previously Untreated Subjects With Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Key Inclusion criterion : 1 . Histologically document FL ( Grade 1 , 2 3A ) 2 . Not previously treat prior anticancer therapy FL 3 . Stage II , III IV disease 4 . At least one measurable lesion ≥ 2 cm long diameter CT and/or MRI scan 5 . Men woman ≥ 18 year age 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Key Exclusion criterion : 1 . Medically apparent central nervous system lymphoma leptomeningeal disease 2 . FL evidence large cell transformation 3 . Any prior history hematologic malignancy besides FL myelodysplasia 4 . History malignancy , except 1 . Malignancy treat curative intent know active disease present ≥5 year first dose study drug felt low risk recurrence treat physician . 2 . Adequately treated nonmelanoma skin cancer lentigomaligna without evidence disease . 3 . Adequately treated carcinoma situ without evidence disease . 5 . Currently active , clinically significant cardiovascular disease myocardial infarction within 6 month screen 6 . Known anaphylaxis IgEmediated hypersensitivity murine proteins component rituximab ( Rituxan® ) 7 . Requires anticoagulation warfarin vitamin K antagonist . 8 . Requires treatment strong CYP3A inhibitor . 9 . Known bleed diathesis hemophilia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pharmacyclics</keyword>
	<keyword>PCYC</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>FL</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>NHL</keyword>
	<keyword>B-cell Lymphoma</keyword>
</DOC>